Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMO-2125 plus ribavirin versus Pegasys plus ribavirin in prior hepatitis C nonresponders
2010-021963-34Phase 2Terminated
- Sponsor
- Aceragen, Inc.
- Start
- Sep 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tilsotolimod in hepatitis C virus infection (2 arms), sponsored by Aceragen, Inc. Primary endpoints: Virologic response and Early virologic response. Started Sep 2010; status: terminated.
02
Drugs
tilsotolimod
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-021963-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021963-34.